Actively Recruiting

Phase 2
Phase 3
Age: 2Years - 16Years
All Genders
NCT07095842

Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)

Led by Sohag University · Updated on 2025-08-05

668

Participants Needed

1

Research Sites

51 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.

CONDITIONS

Official Title

Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)

Who Can Participate

Age: 2Years - 16Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age from 2 to 16 years.
  • Established diagnosis of epilepsy of at least 1 year duration.
  • History of at least 1 episode of convulsive status epilepticus in the preceding 12 months.
Not Eligible

You will not qualify if you...

  • Failure to obtain informed consent.
  • Known allergies or contraindications to ketamine.
  • Known contraindications to intramuscular injection.
  • Presence of another family member included in the same trial.
  • Having subsequent events (only the index event will be included).

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Pediatrics at Sohag University Hospital

Sohag, Egypt, 82524

Actively Recruiting

Loading map...

Research Team

E

Elsayed Abdelkreem

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here